查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1809637

家族性腺瘤息肉症治療市場（依治療類型、給藥途徑、通路、最終用戶和適應症）－2025-2030 年全球預測

Familial Adenomatous Polyposis Treatment Market by Treatment Type, Route Of Administration, Distribution Channel, End User, Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

家族性腺瘤息肉症治療市場預計到 2024 年將達到 12 億美元，到 2025 年將達到 12.9 億美元，到 2030 年將達到 18.6 億美元，複合年成長率為 7.47%。

主要市場統計數據
基準年2024年 12億美元
預計2025年 12.9億美元
預計2030年 18.6億美元
複合年成長率（%） 7.47%

基因突破和綜合護理模式將塑造家族性腺瘤息肉症治療中患者管理的未來

家族性腺瘤息肉症(FAP) 是一種遺傳性疾病，會導致結腸和直腸中出現數百至數千個腺瘤性息肉，如果不及時治療，幾乎肯定會發展為惡性腫瘤。本文將深入探討 FAP 的遺傳基礎：APC 抑癌基因突變會啟動早期息肉的形成，最終導致大腸直腸癌的進展。鑑於早期病變無症狀且癌症風險較高，早期診斷和風險評估的重要性不容忽視。

揭示由創新基因治療技術和以患者為中心的方法推動的家族性腺瘤息肉症治療的變革性轉變

過去十年，一系列科學突破和技術創新徹底改變了家族性腹痛（FAP）的治療模式。其中，精準醫療方法佔據了主導地位，該方法利用基因圖譜對患者風險進行分層，並相應地制定治療方法。 CRISPR/Cas系統等基因編輯技術已從臨床前模型發展到早期人體臨床試驗，並有望從源頭直接修正致病性APC突變。同時，單株抗體設計和標靶遞送系統的進步，帶來了對腫瘤路徑特異性增強的生物化合物，從而減少了脫靶效應並提高了耐受性。

2025 年美國關稅對家族性腺瘤息肉症：獲取動態和成本結構分析

美國將於2025年對進口醫療設備和藥品成分徵收新關稅，這給家庭和行動障礙（FAP）治療供應鏈帶來了多方面的壓力。影響內視鏡系統、專用內視鏡配件和診斷劑的關稅增加了醫療保健提供者的採購成本，導致公共和私營部門的預算緊縮。非類固醇消炎劑和生物製藥製劑也受到類似影響，導致製造成本增加，而這些成本可能會在某些報銷框架下轉嫁給付款人和患者。

治療方式、給藥途徑、通路、最終用戶資料和具體適應症的關鍵細分洞察

在對治療類型進行詳細細分後，可以發現針對不同疾病階段和患者特徵的多種治療方法。聯合治療方案整合多種藥物以協同抑制腺瘤生長，而內視鏡監測則透過大腸鏡檢查和乙狀結腸鏡檢查提供有針對性的介入措施。在藥物治療中，生物治療方法包括旨在糾正 APC 突變的先進基因治療平台，以及針對息肉發展中涉及的關鍵訊號通路的單株抗體。非類固醇消炎劑（分為選擇性 COX-2 抑制劑和傳統非選擇性 NSAID）透過調節與腫瘤轉化相關的發炎連鎖提供額外的化學預防益處。對於有廣泛息肉的患者，手術介入仍然是一個重要選擇，手術範圍從全髂骨、迴腸直腸吻合術到肛門直腸切除術，每種手術在功能結果和生活品質方面都有不同的權衡。

確定影響美洲、歐洲、中東和非洲以及亞太地區遺傳性息肉症治療採用的關鍵區域動態

區域分析顯示，美洲、歐洲、中東和非洲 (EMEA) 以及亞太地區呈現出不同的應用模式和策略重點。在美洲，強大的研究基礎設施和完善的報銷框架支持先進內視鏡技術和生物目標療法的早期應用。北美領先的學術中心正在主導基因編輯方法的臨床試驗，偏遠地區的遠距遠端醫療舉措正在改善監測推廣和依從性監測。

重點介紹在家族性腺瘤息肉症治療生態系統中推動創新夥伴關係和競爭地位的關鍵產業參與者

FAP 治療產業格局涉及多元化的產業相關人員，包括生物製藥創新者、醫療設備製造商和專業服務供應商。領先的生物技術公司已透過利用病毒和非病毒遞送載體靶向 APC 基因校正的早期研究，推進了基因治療候選藥物的研發。現有製藥公司持續最佳化其單株抗體產品線，專注於調節 Wnt 訊號傳導和減少息肉負擔的新型抗原表位。非選擇性和 COX-2 選擇性 NSAID 開發人員正在評估旨在改善胃腸道耐受性和減少全身副作用的下一代製劑。

向行業領導者提出可行的建議，以改善家族性腺瘤息肉症的治療機會並提高患者的治療效果

為了抓住家族性腹膜炎 (FAP) 治療領域的新興機遇，產業領導者應優先投資先進的基因編輯平台和伴隨診斷技術，以實現精準的患者分層。透過發展國內製造能力和替代採購協議來增強供應鏈韌性，將減輕外部關稅壓力對關鍵設備和試劑的影響。同時，與付款人建立基於價值的合作模式，將使報銷獎勵與患者療效而非手術量掛鉤，從而促進高成本生技藥品和基因療法的永續應用。

家族性腺瘤息肉症治療研究的嚴格調查方法的詳細資訊，包括資料來源框架和檢驗過程

本報告的調查方法結合了全面的二手資料和一手資料研究，以確保研究的完整性和深度。二手資料研究廣泛查閱了同行評審文獻、主要胃腸病學和腫瘤學協會發布的臨床指南、監管備案文件和專利資料庫。市場相關情報與政策分析、貿易報告和政府出版刊物進行了交叉檢驗，以了解更廣泛的經濟和監管背景。

彙編家族性腺瘤息肉症治療的策略見解，以指南相關人員推進治療創新和患者照護

本執行摘要提煉了家族性腺瘤息肉症治療領域深入研究的關鍵見解。從基因編輯的突破到生物和藥物療法的增強，精準醫療的進步正在徹底改變臨床實踐，而內視鏡技術和數位健康整合的改進則正在增強檢測、監測和患者參與度。 2025年的關稅格局凸顯了供應鏈彈性和策略性採購的必要性，以維持治療的可負擔性和連續性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章市場動態

  • 一種針對家族性腺瘤息肉症中APC基因突變進行標靶抑制的新型基因編輯方法
  • 內視鏡監測技術在早期發現FAP患者息肉的進展
  • COX-2抑制劑與EGFR抑制劑聯合治療治療FAP的臨床進展
  • 孤兒藥資格認定對新型 FAP 治療藥物開發平臺的監管影響
  • 在 FAP 護理中整合預測性基因分析和個人化化學預防策略
  • FAP患者微創結直腸切除術的擴展及術後生活品質結局調查
  • 生物標記主導的臨床試驗的出現，評估了 FAP 患者群體中的標靶小分子療法
  • 用於即時評估FAP患者術後復發風險的數位健康監測平台
  • 全球 FAP 市場中用於減少息肉負擔的下一代 NSAID 的取得和採用趨勢
  • 生技公司與學術機構建立策略夥伴關係，加速 FAP 治療的轉化研究

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第8章家族性腺瘤息肉症症治療市場（依治療類型）

  • 聯合治療
  • 內視鏡監測
    • 大腸鏡檢查
    • 乙狀結腸鏡檢查
  • 藥物治療
    • 生物製藥
      • 基因治療
      • 單株抗體
    • 非類固醇消炎劑
      • COX-2抑制劑
      • 非選擇性非類固醇抗發炎藥
  • 外科手術干預
    • 切除術
    • 髂骨吻合術
    • 切除術

第9章家族性腺瘤息肉症症治療市場（依給藥途徑）

  • 靜脈
  • 口服
  • 皮下

第 10 章家族性腺瘤息肉症症治療市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 11 章家族性腺瘤息肉症症治療市場（依最終使用者）

  • 居家護理
  • 醫院
  • 專科診所

第 12 章家族性腺瘤息肉症症治療市場（依適應症）

  • 輕度FAP
  • 典型的 FAP

13.美洲家族性腺瘤息肉症症治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 歐洲、中東和非洲家族性腺瘤息肉症症治療市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太家族性腺瘤息肉症症治療市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Eloxx Pharmaceuticals, Inc.
    • Emtora Biosciences
    • KD Pharma Group
    • Biodexa Pharmaceuticals PLC
    • Thermo Fisher Scientific Inc.
    • Olympus Corporation
    • FUJIFILM Holdings Corporation
    • Pentax Ricoh Imaging Company, Ltd.
    • Medtronic plc
    • Siemens Healthcare Private Limited
    • Bayer Corporation
    • Boston Scientific Corporation
    • Parabilis Medicines

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-6B0EA0797510

The Familial Adenomatous Polyposis Treatment Market was valued at USD 1.20 billion in 2024 and is projected to grow to USD 1.29 billion in 2025, with a CAGR of 7.47%, reaching USD 1.86 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.20 billion
Estimated Year [2025] USD 1.29 billion
Forecast Year [2030] USD 1.86 billion
CAGR (%) 7.47%

Charting the Evolution of Familial Adenomatous Polyposis Treatment Fueled by Genetic Breakthroughs and Integrated Care Models Shaping Future Patient Management

Familial Adenomatous Polyposis (FAP) emerges as a hereditary condition marked by the development of hundreds to thousands of adenomatous polyps along the colon and rectum, possessing a near certainty of malignancy if unaddressed. This introduction delves into the genetic underpinnings of FAP, where mutations in the APC tumor suppressor gene initiate early polyp formation and drive progression toward colorectal cancer. The imperatives of early diagnosis and risk assessment cannot be overstated given the asymptomatic nature of initial lesions and the elevated cancer risk profile.

Over recent decades, a spectrum of interventions has evolved to mitigate disease progression and improve long term outcomes. Endoscopic surveillance techniques such as colonoscopy and sigmoidoscopy have established themselves as frontline measures to detect and remove adenomas before malignancy ensues. Pharmacologic therapies, encompassing both biologic agents and nonsteroidal anti-inflammatory drugs, have demonstrated success in polyp reduction and delay of surgical intervention.

Surgical interventions remain a cornerstone for patients at high risk or with extensive polyp burden, with options ranging from colectomy to ileorectal anastomosis and proctocolectomy. In parallel, combination approaches leveraging pharmacologic suppression and endoscopic monitoring have emerged as integrated care pathways. Patient-centric models have begun to incorporate digital health solutions that facilitate remote monitoring and adherence tracking, enabling a more proactive management approach. As research advances, next generation gene therapies and monoclonal antibodies promise to redefine treatment paradigms. The following sections will examine how these developments, alongside regulatory shifts and economic factors, are influencing the direction of FAP treatment and shaping strategic priorities for stakeholders across the healthcare ecosystem.

Illuminating Transformative Shifts in Familial Adenomatous Polyposis Treatment Driven by Innovative Gene Therapies Techniques and Patient-Centric Approaches

Over the past decade, the FAP treatment landscape has been fundamentally reshaped by a confluence of scientific breakthroughs and technological innovations. At the forefront are precision medicine approaches that leverage genetic profiling to stratify patient risk and tailor therapeutic regimens accordingly. Gene editing technologies such as CRISPR/Cas systems are advancing from preclinical models toward early human trials, offering the prospect of directly correcting pathogenic APC mutations at their source. Concurrently, advances in monoclonal antibody design and targeted delivery systems are yielding biologic compounds with enhanced specificity for neoplastic pathways, reducing off target effects and improving tolerability.

Endoscopic techniques have also undergone significant refinement, with high definition imaging and virtual chromoendoscopy enhancing polyp detection rates, while minimally invasive instruments facilitate more efficient resections. Integration of artificial intelligence and machine learning into image analysis is accelerating diagnostic accuracy and procedural efficiency. Digital health platforms are enabling continuous patient monitoring and real time data capture, fostering agile responses to treatment responses and adherence challenges.

These developments have collectively shifted FAP management from reactive polypectomy toward proactive disease interception, emphasizing early molecular intervention and personalized surveillance intervals. The emergence of combination protocols blending systemic pharmacotherapies with precision endoscopy is redefining standard of care, driving improved clinical outcomes and setting new benchmarks for long term disease control.

Regulatory frameworks have also adapted to expedite review of breakthrough therapies, with numerous expedited pathways enabling faster patient access to high potential interventions. Funding initiatives by public and private entities are accelerating early stage research, fostering collaborations that bridge academic discovery with commercial development. As these shifts coalesce, the FAP treatment arena is poised for a new era of innovation that harmonizes clinical excellence with operational agility.

Analyzing the Comprehensive Effects of 2025 United States Tariffs on Familial Adenomatous Polyposis Treatment Supply Chains Access Dynamics and Cost Structures

In 2025, newly enacted tariff measures imposed by the United States on imported medical equipment and pharmaceutical components have exerted multifaceted pressures on the FAP treatment supply chain. Tariffs affecting endoscopy systems, specialized endoscopic accessories, and diagnostic reagents have translated into higher acquisition costs for healthcare providers, challenging budgets in both public and private sectors. Pharmaceutical ingredients for nonsteroidal anti-inflammatory drugs and biologics have similarly been impacted, leading to increased production expenses that may be passed along to payers and patients under certain reimbursement frameworks.

These cumulative effects have prompted institutions to reassess procurement strategies, prioritizing suppliers with domestic manufacturing capabilities or tariff exempt status. Some clinical networks are exploring regional partnerships to establish shared warehousing and distribution hubs, mitigating the inflationary impact of cross border levies. Moreover, the anticipated cost headwinds have intensified negotiations with payers to secure value based contracts that align therapeutic reimbursement with clinical outcomes, rather than volume of procedures.

Clinicians and administrators are also evaluating the viability of alternative pharmacologic formulations that rely on locally sourced active compounds to maintain treatment affordability. While these adaptations have helped stabilize operations, persistent tariff uncertainty complicates long term planning and may hinder the adoption of next generation gene therapies that depend on specialized import components.

Patients have felt the downstream effects of these tariff driven cost shifts, encountering higher out of pocket expenses under certain insurance benefit designs. Delays in equipment replacement cycles have in some cases resulted in longer scheduling lead times for endoscopic evaluations, presenting risks for patients awaiting surveillance procedures. To safeguard patient adherence and clinical outcomes, some providers are exploring patient assistance programs and outcome based payment models that distribute financial risk and promote affordability.

Revealing Critical Segmentation Insights Across Treatment Modalities Administration Routes Distribution Channels End User Profiles and Specific Indications

An in-depth examination of treatment type segmentation reveals a diverse therapeutic arsenal tailored to distinct disease stages and patient profiles. Combination therapy protocols integrate multiple pharmacologic agents to synergistically inhibit adenoma growth, while endoscopic surveillance offers targeted interventions through colonoscopy and sigmoidoscopy procedures. Within pharmacologic therapy, biologic modalities encompass advanced gene therapy platforms designed to correct APC mutations, alongside monoclonal antibodies that target key signaling pathways implicated in polyp development. Nonsteroidal anti-inflammatory drugs, subdivided into selective COX-2 inhibitors and traditional nonselective NSAIDs, provide additional chemopreventive benefits by modulating inflammatory cascades associated with neoplastic transformation. Surgical intervention remains a critical option for individuals with extensive polyp burden, with procedures ranging from total colectomy to ileorectal anastomosis and proctocolectomy, each offering distinct trade-offs in terms of functional outcomes and quality of life.

Route of administration further differentiates therapeutic choices, with intravenous infusions employed for certain biologic agents, oral formulations enabling outpatient accessibility for chemopreventive drugs, and subcutaneous injections serving as a convenient delivery method for selected monoclonal therapies. Distribution channel dynamics influence treatment acquisition, as hospital pharmacies maintain institutional inventories for inpatient and outpatient care, online pharmacies offer streamlined ordering and home delivery, and retail pharmacies support community-based dispensing. End users span home care settings that facilitate patient self-administration under remote supervision, hospitals that deliver complex procedural and pharmacologic regimens, and specialty clinics focusing on advanced diagnostics and interventional strategies. Finally, indication specificities distinguish between attenuated FAP presentations, characterized by fewer polyps and later onset, and classic FAP profiles with early, aggressive polyp proliferation, guiding tailored therapeutic pathways across the patient journey.

Illuminating Pivotal Regional Dynamics Shaping Familial Adenomatous Polyposis Treatment Adoption in the Americas Europe Middle East Africa and Asia Pacific

Regional analysis underscores distinct adoption patterns and strategic priorities across the Americas, Europe Middle East Africa (EMEA) and Asia Pacific. In the Americas, robust research infrastructure and established reimbursement frameworks have supported early adoption of advanced endoscopic techniques and targeted biologic therapies. Leading academic centers in North America are spearheading clinical trials for gene editing approaches, while telemedicine initiatives in remote areas have improved surveillance outreach and adherence monitoring.

Within Europe, Middle East and Africa, treatment landscapes exhibit heterogeneity driven by national healthcare policies and resource availability. Western European nations have integrated precision therapeutics within standardized care pathways, whereas certain Middle Eastern and African markets are prioritizing capacity building for endoscopic services and pharmacologic accessibility. Cross-regional collaborations are emerging to harmonize regulatory guidelines, enabling streamlined approvals for innovative agents and equipment.

In the Asia Pacific region, rising awareness of hereditary colorectal disorders is fueling investment in diagnostic services and patient education programs. Governments are incentivizing local production of generic chemopreventive agents and facilitating technology transfer partnerships to enhance access. Infrastructure expansion in Southeast Asia has improved hospital pharmacy networks, while online platforms are increasingly utilized to bridge gaps in distribution. Specialty clinics in key urban centers are consolidating multidisciplinary care teams, reflecting a shift toward integrated management models.

Looking ahead, cross regional knowledge exchange and public private partnerships will be critical to harmonize standards of care and disseminate best practices, ensuring that innovations in FAP management deliver maximum patient benefit on a global scale.

Highlighting Leading Industry Players Driving Innovation Partnerships and Competitive Positioning within the Familial Adenomatous Polyposis Treatment Ecosystem

Industry participants within the FAP treatment landscape encompass a spectrum of biopharmaceutical innovators, medical device manufacturers and specialized service providers. Leading biotechs have advanced gene therapy candidates through early phase studies, harnessing viral and nonviral delivery vectors to target APC gene correction. Established pharmaceutical firms continue to optimize monoclonal antibody pipelines, focusing on novel epitopes that modulate Wnt signaling and reduce polyp burden. Nonselective and COX-2 selective NSAID developers are evaluating next generation formulations aimed at enhancing gastrointestinal tolerability and reducing systemic side effects.

Medical device companies are driving advancements in endoscopic hardware, introducing flexible platforms with integrated high resolution imaging, artificial intelligence assistance and accessory compatibility for streamlined polypectomies. Collaborations between diagnostic specialists and imaging software providers are yielding real time analytics that inform procedural decision making. On the distribution front, pharmacy networks and logistics partners are refining cold chain protocols to support the growing portfolio of temperature sensitive biologics and gene therapy products.

Strategic alliances between biopharma and academic centers are accelerating translational research, while partnerships with contract research organizations are expediting trial operations. Early stage companies have leveraged venture funding to validate proprietary delivery technologies, attracting attention from larger players seeking acquisition or licensing agreements. Furthermore, the pursuit of orphan drug designations and expedited regulatory pathways is incentivizing research investment, with several companies leveraging exclusivity provisions to support long term development programs. Intellectual property strategies and patent litigation trends will shape the competitive landscape as novel therapies progress toward commercialization.

Formulating Actionable Recommendations for Industry Leaders to Improve Access and Enhance Patient Outcomes in Familial Adenomatous Polyposis Treatment

To capitalize on emerging opportunities within the FAP treatment arena, industry leaders should prioritize investment in advanced gene editing platforms and companion diagnostics that enable precise patient stratification. Strengthening supply chain resilience through the development of domestic manufacturing capabilities or alternative sourcing agreements will mitigate the impact of external tariff pressures on critical equipment and reagents. Concurrently, establishing value based collaboration models with payers can align reimbursement incentives with patient outcomes rather than procedural volume, fostering sustainable adoption of high cost biologics and gene therapies.

It is essential to integrate digital health solutions into care pathways, leveraging remote monitoring tools and artificial intelligence driven decision support to enhance adherence, optimize surveillance schedules and reduce the burden on clinical resources. Partnerships with technology providers and data analytics firms can unlock real world evidence that informs continuous improvement and regulatory filings. Engagement with policymakers and industry associations should be intensified to advocate for balanced trade policies and streamlined approval processes, ensuring uninterrupted access to innovative treatments.

In parallel, developing risk management frameworks and scenario planning exercises will equip leadership teams to anticipate regulatory adjustments, tariff shifts and competitive moves. Investing in real time data platforms that offer predictive insights into patient volumes, therapy responses and operational bottlenecks will further enhance strategic resilience. Lastly, cultivating multidisciplinary care networks that unite gastroenterologists, genetic counselors, surgeons and allied health professionals will drive holistic patient management and improve quality of life outcomes.

Detailing the Rigorous Research Methodology of the Familial Adenomatous Polyposis Treatment Study Including Data Sources Frameworks and Validation Processes

The methodology underpinning this report combines comprehensive secondary and primary research to ensure the integrity and depth of insights. Secondary research involved an exhaustive review of peer reviewed literature, clinical guidelines published by leading gastroenterology and oncology societies, regulatory filings and patent databases. Market related intelligence was cross validated with policy analyses, trade reports and government publications to capture the broader economic and regulatory context.

Primary research incorporated structured interviews and surveys with key opinion leaders, including gastroenterologists specializing in hereditary colorectal disorders, surgical oncologists, clinical geneticists and supply chain experts. Additional discussions with hospital administrators, pharmacy directors and payer representatives provided practical perspectives on procurement challenges, reimbursement dynamics and patient access considerations. Data from these interactions were rigorously triangulated with secondary sources to resolve discrepancies and refine thematic conclusions.

An analytical framework guided segmentation by treatment type, route of administration, distribution channel, end user and indication, facilitating targeted insight generation. Regional analyses employed economic and healthcare infrastructure metrics to contextualize adoption patterns. Ethical oversight and patient consent protocols were carefully integrated into primary research activities, ensuring compliance with data privacy regulations and upholding participant confidentiality throughout the study process. Quality control measures included peer reviews by subject matter experts and systematic data verification to uphold factual accuracy. This robust approach ensures that the findings and recommendations reflect a balanced, evidence based understanding of the FAP treatment landscape.

Summarizing Strategic Insights into Familial Adenomatous Polyposis Treatment to Guide Stakeholders in Advancing Therapeutic Innovation and Patient Care

This executive summary distills the critical insights gleaned from a thorough examination of the familial adenomatous polyposis treatment domain. Advances in precision medicine, from gene editing breakthroughs to enhanced biologic and pharmacologic therapies, are revolutionizing clinical practice, while improvements in endoscopic technology and digital health integration are elevating detection, surveillance and patient engagement. The 2025 tariff landscape underscores the necessity of supply chain flexibility and strategic sourcing to preserve treatment affordability and continuity.

Segmentation analysis highlights the diverse modalities and delivery routes that shape tailored care pathways, as well as the pivotal role of distribution channels and end user environments in facilitating accessibility. Regional dynamics reveal a tapestry of healthcare ecosystems, each advancing FAP management in alignment with local priorities and resource capacities. Industry collaboration, characterized by partnerships between biotechs, device manufacturers and academic institutions, is accelerating translational research and fostering a competitive yet cooperative landscape.

Actionable recommendations emphasize the importance of investing in domestic manufacturing, value based contracting, digital platforms and multidisciplinary networks to drive sustainable innovation and enhance patient outcomes. Continuous monitoring of emerging clinical trial results and policy developments will be essential to maintain the relevance of these insights and to inform subsequent updates to the report. By applying these strategic imperatives, stakeholders across the healthcare continuum can navigate evolving challenges and deliver more effective, patient centered solutions for those affected by this hereditary condition.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Emerging gene editing approaches for targeted suppression of APC mutations in familial adenomatous polyposis
  • 5.2. Advancements in endoscopic surveillance techniques for earlier polyp detection in FAP patients
  • 5.3. Clinical progression of combination therapy using COX-2 inhibitors and EGFR blockers in FAP management
  • 5.4. Regulatory impact of orphan drug designations on novel FAP treatment development pipelines
  • 5.5. Integration of predictive genetic profiling and personalized chemoprevention strategies in FAP care
  • 5.6. Expansion of minimally invasive colectomy procedures and postoperative quality of life outcomes research in FAP
  • 5.7. Emergence of biomarker-driven clinical trials evaluating targeted small molecule therapies in FAP cohorts
  • 5.8. Digital health monitoring platforms for real-time assessment of post-surgical recurrence risk in FAP patients
  • 5.9. Accessibility and adoption trends of next-generation NSAIDs for polyp burden reduction in global FAP markets
  • 5.10. Strategic partnerships between biotechs and academic centers accelerating translational research in FAP therapeutics

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Familial Adenomatous Polyposis Treatment Market, by Treatment Type

  • 8.1. Introduction
  • 8.2. Combination Therapy
  • 8.3. Endoscopic Surveillance
    • 8.3.1. Colonoscopy
    • 8.3.2. Sigmoidoscopy
  • 8.4. Pharmacologic Therapy
    • 8.4.1. Biologics
      • 8.4.1.1. Gene Therapy
      • 8.4.1.2. Monoclonal Antibodies
    • 8.4.2. Nonsteroidal Anti-Inflammatory Drugs
      • 8.4.2.1. COX-2 Inhibitors
      • 8.4.2.2. Nonselective NSAIDs
  • 8.5. Surgical Intervention
    • 8.5.1. Colectomy
    • 8.5.2. Ileorectal Anastomosis
    • 8.5.3. Proctocolectomy

9. Familial Adenomatous Polyposis Treatment Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Familial Adenomatous Polyposis Treatment Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Familial Adenomatous Polyposis Treatment Market, by End User

  • 11.1. Introduction
  • 11.2. Home Care
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Familial Adenomatous Polyposis Treatment Market, by Indication

  • 12.1. Introduction
  • 12.2. Attenuated FAP
  • 12.3. Classic FAP

13. Americas Familial Adenomatous Polyposis Treatment Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Familial Adenomatous Polyposis Treatment Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Familial Adenomatous Polyposis Treatment Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Eloxx Pharmaceuticals, Inc.
    • 16.3.2. Emtora Biosciences
    • 16.3.3. KD Pharma Group
    • 16.3.4. Biodexa Pharmaceuticals PLC
    • 16.3.5. Thermo Fisher Scientific Inc.
    • 16.3.6. Olympus Corporation
    • 16.3.7. FUJIFILM Holdings Corporation
    • 16.3.8. Pentax Ricoh Imaging Company, Ltd.
    • 16.3.9. Medtronic plc
    • 16.3.10. Siemens Healthcare Private Limited
    • 16.3.11. Bayer Corporation
    • 16.3.12. Boston Scientific Corporation
    • 16.3.13. Parabilis Medicines

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 15. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 17. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 21. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 23. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHAI
  • FIGURE 26. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHSTATISTICS
  • FIGURE 27. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHCONTACTS
  • FIGURE 28. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2024 (USD THOUSAND)
  • TABLE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2025-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD THOUSAND)
  • TABLE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 16. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 18. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 20. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 22. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 24. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 26. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 28. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 30. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 31. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 32. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 33. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 34. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 35. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 36. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 37. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 38. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 39. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 40. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 41. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 42. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 43. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 44. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 45. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 46. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 47. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 48. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 49. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 50. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 51. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 52. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 53. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 54. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 55. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 56. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 57. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 58. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 59. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 60. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 61. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 62. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 63. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 64. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 65. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 66. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 67. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 68. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 69. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 70. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 71. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 72. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 73. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 74. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 75. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 76. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 77. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 78. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 79. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY REGION, 2018-2024 (USD THOUSAND)
  • TABLE 80. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY REGION, 2025-2030 (USD THOUSAND)
  • TABLE 81. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 82. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 83. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 84. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 85. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 86. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 87. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 88. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 89. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 90. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 91. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 92. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 93. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 94. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 95. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 96. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 97. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 98. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 99. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 100. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 101. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD THOUSAND)
  • TABLE 102. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD THOUSAND)
  • TABLE 103. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 104. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 105. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 106. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 107. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 108. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 109. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 110. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 111. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 112. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 113. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 114. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 115. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 116. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 117. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 118. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 119. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 120. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 121. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 122. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 123. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD THOUSAND)
  • TABLE 124. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD THOUSAND)
  • TABLE 125. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 126. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 127. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 128. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 129. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 130. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 131. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 132. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 133. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 134. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 135. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 136. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 137. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 138. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 139. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 140. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 141. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 142. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 143. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 144. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 145. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 146. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 147. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 148. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 149. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 150. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 151. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 152. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 153. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 154. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 155. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 156. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 157. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 158. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 159. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 160. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 161. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 162. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 163. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 164. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 165. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 166. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 167. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 168. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 169. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 170. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 171. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 172. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 173. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 174. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 175. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 176. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 177. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 178. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 179. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 180. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 181. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 182. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 183. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 184. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 185. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 186. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 187. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 188. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 189. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 190. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 191. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 192. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 193. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 194. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 195. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 196. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 197. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 198. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 199. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 200. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 201. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 202. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 203. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 204. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD THOUSAND)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD THOUSAND)
  • TABLE 227. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 228. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 229. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 230. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 231. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 232. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 233. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 234. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 235. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 236. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 237. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 238. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 239. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 240. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 241. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 242. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 243. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 244. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
  • TABLE 245. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
  • TABLE 246. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
  • TABLE 247. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
  • TABLE 248. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
  • TABLE 249. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
  • TABLE 250. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
  • TABLE 251. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
  • TABLE 252. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
  • TABLE 253. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
  • TABLE 254. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
  • TABLE 255. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
  • TABLE 256. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
  • TABLE 257. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
  • TABLE 258. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
  • TABLE 259. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
  • TABLE 260. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
  • TABLE 261. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
  • TABLE 262. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
  • TABLE 263. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
  • TABLE 264. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2